For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
11
views
35
references
 Top references
cited by
42
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      3,244
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Three-Year Outcomes With the Absorb Bioresorbable Scaffold : Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3 years after coronary artery implantation. The safety and effectiveness of BVS through this critical 3-year period have not been characterized.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.

          Patrick W. Serruys, Bernard Chevalier, Yohei Sotomi … (2016)
          No medium-term data are available on the random comparison between everolimus-eluting bioresorbable vascular scaffolds and everolimus-eluting metallic stents. The study aims to demonstrate two mechanistic properties of the bioresorbable scaffold: increase in luminal dimensions as a result of recovered vasomotion of the scaffolded vessel.
          Article 0 comments Cited 149 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

            Stephen G Ellis, Dean Kereiakes, D Metzger … (2015)
            In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the metallic stent frame in the coronary-vessel wall. Bioresorbable vascular scaffolds have been developed to attempt to improve long-term outcomes.
            Article 0 comments Cited 143 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.

              Tullio Palmerini, UMBERTO BENEDETTO, Giuseppe Biondi-Zoccai … (2015)
              Previous meta-analyses have investigated the relative safety and efficacy profiles of different types of drug-eluting stents (DES) and bare-metal stents (BMS); however, most prior trials in these meta-analyses reported follow-up to only 1 year, and as such, the relative long-term safety and efficacy of these devices are unknown. Many recent studies have now reported extended follow-up data.
              Article 0 comments Cited 136 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: Circulation
                Abbreviated Title: Circulation
                Publisher: Ovid Technologies (Wolters Kluwer Health)
                ISSN (Print): 0009-7322
                ISSN (Electronic): 1524-4539
                Publication date Created: January 30 2018
                Publication date (Print): January 30 2018
                Volume: 137
                Issue: 5
                Pages: 464-479
                Affiliations
                [1 ]New York–Presbyterian Hospital/Columbia University Medical Center, New York (Z.A.A., G.W.S.)
                [2 ]Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (Z.A.A., G.W.S.)
                [3 ]Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China (R.G.)
                [4 ]Kyoto University Hospital, Japan (T.K.)
                [5 ]Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands (Y.O.)
                [6 ]The Christ Hospital, Heart and Vascular Center, Lindner Research Center, Cincinnati, OH (D.J.K.)
                [7 ]Cleveland Clinic, OH (S.G.E.)
                [8 ]Institut Cardiovasculaire Paris Sud, Massy, France (B.C.)
                [9 ]Abbott Vascular, Santa Clara, CA (M.-t.V., Z.Z., C.A.S.)
                [10 ]International Centre for Cardiovascular Health, Imperial College, London, UK (P.W.S.)
                Article
                DOI: 10.1161/CIRCULATIONAHA.117.031843
                PubMed ID: 29089314
                SO-VID: 51ad45a6-faef-47d4-9503-6c73818e533b
                Copyright © © 2018
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content3,244

                See all similar

                Cited by42

                See all cited by

                Most referenced authors846

                See all reference authors